Donald McDonnell, PhD, associate director for Translational Research, DCI, receives prestigious St. Patrick's Day Irish science medal for contributions to academia and industry.
“Each time there are new diagnostic tools and there are new treatments. I've been following the wave for 22 years now." — prostate cancer survivor Michael Johnstone.
Duke Cancer Institute researchers Jiaoti Huang, MD, PhD, Brant Inman, MD, and Qing Cheng, PhD, have identified a molecular signature that can spot aggressive cells.
Astellas Pharma Inc. announced on May 4 that the European Commission has approved enzalutamide for adult men with metastatic hormone-sensitive prostate cancer.
This OHE-hosted talk featured director of the Patierno/George/Freedman Lab Jennifer Freedman, PhD, and postdocs Tyler Allen, PhD, and Sean Piwarski, PhD.
Various genetic alterations in circulating tumor cells were associated with clinical outcomes and resistance to hormone therapy in patients with mCRPC.
Susan Halabi, PhD, is co-leading a project to create a large international registry of data from prostate cancer patients treated with various PARP inhibitors.
DCI pathologist Jung Wook Park, PhD, mentored by Jiaoti Huang, MD, PhD, and Andrew Armstrong, MD, MSc, has received a Prostate Cancer Foundation Young Investigator Award.
DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.
ICYMI the AACI's Physician Clinical Leadership Initiative (PCLI) presented a two-part webinar series on hereditary cancer programs and cancer risk assessment.
Andrew Armstrong, MD, found that treatment with enzalutamide and ADT significantly reduced the risk of metastasis or death over time in men with mHSPC.
While there have been many successes with newer chemotherapies, targeted therapies, and immunotherapies, many cancer types in the human population don...
When Robert “Bob” List, 73, a retired colonel with the U.S. Marine Corps, was diagnosed with stage 2 prostate cancer, he immediately began to research the “enemy” threat.
Black men are underrepresented in clinical trials for prostate cancer, despite an almost two-fold greater incidence and mortality of disease in black versus white populations.
Five years after surgery to treat prostate cancer, Steele Dewey of Charlotte, North Carolina was told that the cancer had spread. He chose Dan George, MD, at Duke.
When his dad passed away from cancer, Myles Owens IV launched a clothing line in his memory. Part of the proceeds benefit Duke Cancer Institute research.
The Symons family has taken the famous song lyric “from sea to shining sea” to an entirely new level. Rather than simply traveling from state-to-state...
While searching for a non-invasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some bl...
Summer may have just started, but Mo Bros everywhere are already thinking about fall. Having raised almost $20,000 for the Movember Foundation and the...
When Robert “Bob” List, 72, a retired colonel with the U.S. Marine Corps, was diagnosed with stage 2 prostate cancer in June 2006, he immediately bega...
The Big Biscuit Showdown, featuring 13 teams of chefs from Rise Biscuits & Donuts, was held Thursday, July 27, at The Rickhouse in Durham.The benefit ...
Patients with lymph-only metastasis have the longest overall survival, while those with liver involvement fare worst. Lung and bone metastasis fall in...
On the first day of November Duke men, known as Mo Bros by the Movember Foundation, shaved down and prepared mentally and physically for a hairy month...
Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors ...
Allen Spalt is a retired enviromentalist and loving husband, father and grandfather. He’s also the quintessential globe trotter. The 74-year-old Carrb...
Duke Cancer Institute (DCI) recently announced the formation of a new center, Duke Prostate and Urologic Cancer Center, a center of excellence support...
Shared decision-making in health care has been touted as a way to include patient preferences in treatment plans, better balance treatment risks and b...